The aim of this study is to determine whether oral Chinese herbal medicine in combination secukinumab is effective and safe in the treatment of severe psoriasis.
The aim of this study is to determine whether oral Chinese herbal medicine in combination with secukinumab is effective and safe in the treatment of severe psoriasis. Eligible participants will be treated with oral Chinese herbal medicine and secukinumab concurrently. No controlled group will be set up in this trial. The primary outcome is time to relapse. Secondary outcomes include Psoriasis Area and Severity Index (PASI) 75/90, PASI score reduction rate, physician's global assessment (PGA) score, body surface area (BSA) score, visual analogue scale (VAS) score, dermatology life quality index (QLQI) and Skindex 16.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangzhou, Guangdong, China
RECRUITINGMedian time to relapse
Median time to relapse is a time interval. The time interval will be recorded between the end of treatment and the occurrence of relapse. Relapse was defined as loss of \> 50% of maximum Psoriasis Area and Severity Index (PASI) improvement compared with pretreatment baseline.
Time frame: Through study completion, an average of 1 year
Psoriasis Area and Severity Index (PASI) score
The improvement in Psoriasis Area and Severity Index (PASI) score from baseline after treatment; the scale scores ranged from 0-72. The higher the scores are, the more severe the patients suffer
Time frame: Assessment will be conducted at week 0, 1, 2, 3, 4, and every four weeks throughout the remaining period the this trial, an average of 1 year
PASI-75
The proportion of patients who achieve at least 75% improvement in PASI score from baseline.
Time frame: 16 weeks after treatment
PASI-90
The proportion of patients who achieve at least 90% improvement in PASI score from baseline.
Time frame: 16 weeks after treatment
Physician's global assessment (PGA) score
Physician's global assessment for the condition
Time frame: Assessment will be conducted on week 0, 1, 2, 3, 4, and every four weeks throughout the remaining period the this trial, an average of 1 year.
Pruritus Scores on the Visual Analogue Scale
Pruritus will be assessed using the Visual Analogue Scales; The Scale scores ranged from 0-10; the higher the scores are, the more itching the patients suffer.
Time frame: Assessment will be conducted on week 0, 1, 2, 3, 4, and every four weeks throughout the remaining period the this trial, an average of 1 year.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
BSA
the Body Surface Area
Time frame: Assessment will be conducted on week 0, 1, 2, 3, 4, and every four weeks throughout the remaining period the this trial, an average of 1 year.
Dermatology Life Quality Index (DLQI)
Questionnaire for disease-specific quality of life
Time frame: Assessment will be conducted on week 0, 16 and the end of study completion (once relapse occurs, an average of 1 year).
Skindex16
Questionnaire for disease-specific quality of life
Time frame: Assessment will be conducted on week 0, 16 and the end of study completion (once relapse occurs, an average of 1 year).
patients' attitudes, expectation and experience
Semi-structured individual interview will be conducted to explore patients' understanding and expectation for the combination therapy used in this study. Patients' experience of using the combination therapy will be recorded as well.
Time frame: Interview will be conducted on week 0, 16 and the end of study completion (once relapse occurs, an average of 1 year).